Chemed Corp. (CHE) Shares Sold by Sivik Global Healthcare LLC
Sivik Global Healthcare LLC cut its stake in shares of Chemed Corp. (NYSE:CHE) by 16.7% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 12,500 shares of the company’s stock after selling 2,500 shares during the period. Sivik Global Healthcare LLC owned about 0.08% of Chemed Corp. worth $2,557,000 at the end of the most recent quarter.
A number of other large investors also recently bought and sold shares of the business. BNP Paribas Arbitrage SA raised its position in Chemed Corp. by 1.0% during the first quarter. BNP Paribas Arbitrage SA now owns 3,891 shares of the company’s stock worth $711,000 after acquiring an additional 39 shares during the period. Municipal Employees Retirement System of Michigan raised its position in Chemed Corp. by 1.1% during the first quarter. Municipal Employees Retirement System of Michigan now owns 3,700 shares of the company’s stock worth $676,000 after acquiring an additional 40 shares during the period. Capstone Asset Management Co. raised its position in Chemed Corp. by 2.7% during the second quarter. Capstone Asset Management Co. now owns 1,857 shares of the company’s stock worth $380,000 after acquiring an additional 49 shares during the period. Nisa Investment Advisors LLC raised its position in Chemed Corp. by 0.4% during the second quarter. Nisa Investment Advisors LLC now owns 11,600 shares of the company’s stock worth $2,373,000 after acquiring an additional 50 shares during the period. Finally, Amalgamated Bank raised its position in Chemed Corp. by 2.9% during the second quarter. Amalgamated Bank now owns 2,203 shares of the company’s stock worth $451,000 after acquiring an additional 62 shares during the period. Institutional investors own 96.96% of the company’s stock.
Chemed Corp. (NYSE:CHE) traded up 1.38% during midday trading on Friday, hitting $195.88. 211,555 shares of the stock were exchanged. The stock has a market cap of $3.13 billion, a P/E ratio of 48.59 and a beta of 1.14. Chemed Corp. has a one year low of $132.92 and a one year high of $216.01. The firm has a 50-day moving average price of $193.71 and a 200-day moving average price of $195.72.
Chemed Corp. (NYSE:CHE) last released its quarterly earnings results on Tuesday, July 25th. The company reported $2.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.89 by $0.26. The business had revenue of $415.06 million during the quarter, compared to the consensus estimate of $407.56 million. Chemed Corp. had a return on equity of 26.18% and a net margin of 4.16%. The business’s revenue was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.80 EPS. On average, equities research analysts anticipate that Chemed Corp. will post $8.21 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Monday, August 14th were paid a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 0.57%. The ex-dividend date was Thursday, August 10th. This is an increase from Chemed Corp.’s previous quarterly dividend of $0.26. Chemed Corp.’s payout ratio is 28.07%.
CHE has been the subject of a number of research analyst reports. BidaskClub cut shares of Chemed Corp. from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 22nd. Zacks Investment Research upgraded shares of Chemed Corp. from a “hold” rating to a “buy” rating and set a $213.00 price objective for the company in a research report on Wednesday, August 23rd. TheStreet cut shares of Chemed Corp. from a “b+” rating to a “c+” rating in a research report on Tuesday, July 25th. Royal Bank Of Canada restated a “hold” rating and set a $209.00 price objective on shares of Chemed Corp. in a research report on Friday, September 1st. Finally, Oppenheimer Holdings, Inc. upped their price objective on shares of Chemed Corp. from $200.00 to $220.00 and gave the stock an “outperform” rating in a research report on Thursday, July 27th. Three analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Chemed Corp. currently has an average rating of “Hold” and a consensus target price of $214.00.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2017/09/17/chemed-corp-che-shares-sold-by-sivik-global-healthcare-llc.html.
In other news, insider Spencer S. Lee sold 1,000 shares of Chemed Corp. stock in a transaction on Friday, September 1st. The stock was sold at an average price of $197.46, for a total transaction of $197,460.00. Following the completion of the transaction, the insider now owns 37,809 shares of the company’s stock, valued at approximately $7,465,765.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Kevin J. Mcnamara sold 15,000 shares of Chemed Corp. stock in a transaction on Friday, July 28th. The stock was sold at an average price of $201.16, for a total value of $3,017,400.00. Following the transaction, the insider now directly owns 173,801 shares of the company’s stock, valued at approximately $34,961,809.16. The disclosure for this sale can be found here. Insiders own 5.32% of the company’s stock.
About Chemed Corp.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.